Boston Scientific Announces Enrollment of First Patient in Benign Stricture Study of WallFlex(R) Biliary RX Stent

NATICK, Massachusetts and DUSSELDORF, Germany, January 15 - Boston Scientific Corporation (NYSE: BSX) today announced that the first
patient has been enrolled in a clinical trial to evaluate its WallFlex(R)
Biliary RX Fully Covered Stent for the treatment of benign bile duct
strictures. This multi-center, prospective study plans to enroll 187 patients
at 11 centers(1) worldwide over the next 18 months. The first patient was
enrolled by Professor Horst Neuhaus at the Evangelisches Krankenhaus in
Dusseldorf, Germany. Lead Investigators in the study are Professor Jacques
Deviere of Hospital Erasme in Brussels, and Professor Guido Costamagna of
Policlinico A. Gemelli in Rome.

"We are pleased to have enrolled the first patient in this important
trial to assess the WallFlex Biliary RX Fully Covered Stent as a potential
option for the treatment of benign biliary strictures," said Professor
Neuhaus. "The WallFlex Stent has proved to be effective in the management of
malignant bile duct strictures, and the start of this trial represents a
significant clinical milestone in determining optimal treatment strategies
for patients with benign bile duct strictures."

The trial will evaluate the removal of the stents from patients with
benign bile duct strictures as well as the effectiveness of temporary
stenting for long-term, benign biliary stricture resolution. The study will
include patients with bile duct strictures associated with post liver
transplant anastomosis, prior abdominal surgery such as cholecystectomy (gall
bladder removal) and chronic pancreatitis (inflammation of the pancreas). The
WallFlex Biliary RX Stent will remain in the patients four to 12 months
depending on the nature of the stricture. Patients will be followed for five
years after stent removal.

"We believe this trial is the most comprehensive of its kind and is
critical to advancing our knowledge of fully covered, self-expanding metal
stenting as an endoscopic treatment for benign biliary strictures," said
Professor Deviere. "Use of the WallFlex Biliary RX Fully Covered Stents in
these patients may provide significant benefits as a minimally invasive
alternative to surgery."

The WallFlex Biliary RX Stent is constructed of braided, platinum-cored
Nitinol wire (Platinol(TM) Wire) and features three key components: radial
force to help maintain duct patency and resist migration, flexibility to aid
in conforming to tortuous anatomies and full-length radiopacity to enhance
stent visibility under fluoroscopy. The WallFlex Biliary RX family of stents
is available in fully covered, partially covered and uncovered versions. The
covered stents have a silicone polymer coating designed to reduce the
potential for tumor ingrowth, and an integrated retrieval loop for removing
or repositioning the stent during the initial procedure in the event of
incorrect placement.

"The start of patient enrollment in the WallFlex study is an important
achievement for Boston Scientific, and we look forward to continuing
enrollment in additional countries in the near future," said Michael Phalen,
President, Boston Scientific Endoscopy. "The WallFlex Biliary RX Stent System
was designed with physician feedback in mind, reinforcing our commitment to
providing physicians with the world's leading technologies to treat and
diagnose digestive diseases."

The WallFlex Biliary RX Stents have received U.S. Food and Drug
Administration clearance and CE Mark approval and are indicated for the
palliative treatment of biliary strictures produced by malignant neoplasms.
The safety and effectiveness of the WallFlex Biliary RX Stenting System for
use in the vascular system have not been established.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of
medical devices whose products are used in a broad range of interventional
medical specialties. For more information, please visit:
www.bostonscientific.com.

About Boston Scientific Endoscopy

Boston Scientific Endoscopy develops innovative technology for less
invasive, more efficient gastrointestinal procedures.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements. Boston Scientific
wishes to caution the reader of this press release that actual results may
differ from those discussed in the forward-looking statements and may be
adversely affected by, among other things, risks associated with new product
development and commercialization, clinical trials, intellectual property,
regulatory approvals, competitive offerings, Boston Scientific's overall
business strategy, and other factors described in Boston Scientific's filings
with the Securities and Exchange Commission.

(1) Centers are in: Australia, Austria, Belgium, Canada, France, Germany,
India, Italy, the Netherlands and Spain.

    CONTACT:      Geraldine Varoqui
                  Boston Scientific
                  Public Relations International
                  +49-170-782-85-58
                  varoquig@bsci.com

Geraldine Varoqui, Public Relations International, Boston Scientific, +49-170-782-85-58, varoquig at bsci.com